A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Recruiting

Phase 3

OCU400A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Sponsor:

Ocugen

Code:

NCT06388200

Conditions

Retinitis Pigmentosa

Eligibility Criteria

Sex: All

Age: 3+

Healthy Volunteers: Not accepted

Interventions

Sub-Retinal Administration of OCU400-301

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-14. This information was provided to ClinicalTrials.gov by Ocugen on 2026-01-08.